Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial

DOI: 10.1186/s12986-019-0331-1

Keywords: Non-alcoholic fatty liver disease, Nano-curcumin, Obesity, Overweight, Iran

Full-Text   Cite this paper   Add to My Lib

Abstract:

Flowchart of participants with overweight/obesity and NAFL

Full-Text